Telavancin

Telavancin Glycopeptide 2007 2008 2009 cSSSIs caused by G+ bacteria including MRSA... [Pg.352]

Telavancin (28 Vibativ ) Vancomycin (27) Antibiotic Semi-synthetic NP Microbial Antibacterial Inhibits bacterial cell wall synhiesis 304-311... [Pg.25]

Telavancin (28 Vibativ Theravance/Astellas Pharmaceuticals, 2009), was discovered by Theravance as an antibacterial agent, and was developed in partnership with Astellas. " Telavancin (28), a semi-synthetic derivative of vancomycin (27), inhibits bacterial growth by binding to... [Pg.37]

Leadbetter MR, Adams SM, Bazzini B, Fatheree PR, Karr DE, Krause KM, Lam BM, Linsell MS, Nodwell MB, Pace JL, Quasi K, Shaw JP, Soriano E, Trapp SG Villena JD, Wu TX, Christensen BG Judice JK. (2004) Hydrophobic vancomycin derivatives with improved ADME properties Discovery of telavancin (TD-6424). J Antibiot 57 326-336. [Pg.139]

Kanafani ZA. (2006) Telavancin A new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti-Infect Ther 4 743-749. [Pg.139]

Laohavaleeson S, Kuti JL, Nicolau DP. (2007) Telavancin A novel lipoglycopeptide for serious Gram-positive infections. Expert Opin Invest Drugs 16 347-357. [Pg.139]

Leonard SN, Rybak MJ Telavancin An antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 2008 28 458. [PMID 18363530]... [Pg.1001]

Telavancin Complicated skin and skin structure infections Theravance (South San Francisco, CA) 9/11/2009... [Pg.246]

Vancomycin, a natural product that was first approved in 1955, is still the prototype for structural variations with the same mechanism of action the binding to the terminal L-Lys-D-Ala-D-Ala tripeptide in Gram-positive cell wall biosynthesis. The compounds below are semi-synthetic modifications of the same basic structural class (glycopeptides) as the prototype vancomycin, thus following in the chemical footsteps of the (1-lactams currently, there are three semi-synthetic glycopeptides, oritavancin 39, telavancin 40 and dalba-vancin 41, in late stage clinical development. [Pg.15]

Dalbavancin, oritavancin and telavancin are a new class of semi-synthetic glycopeptide antibiotics and are now under clinical trial. These antibiotics have important side chains and exhibit potent activity against gram-positive bacteria, including MRSA and VRE (Fig. 14, Tables 3,4). [Pg.705]

Telavancin is a new semisynthetic glycopeptide antibiotic with rapid bactericidal activity for gram-positive bacteria, which is mediated by a pair of biochemically distinct mechanisms inhibition of bacterial membrane phospholipids synthesis and inhibition of bacterial cell wall... [Pg.705]

S. Barriere, E. Center, E. Spencer, M. Kitt, D. Hoelscher, and J. Morganroth, Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 44 689-695 (2004). [Pg.363]

Telavancin (TD-6424), a second-generation semisynthetic lipoglycopeptide antibacterial agent based on a vancomycin scaffold. It exhibits potent in-vitro antibacterial action against a broad array of important Gram-positive pathogens [J. L. Pace, G. Yang, Biochem. Pharmacol. 2006, 71, 968]. [Pg.366]

Zhanel GC, Calic D, SchweizerF, Zelenitsky S, Adam H, Lagace-Wiens PRS, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA (2010) New lipoglycopeptides a comparative review of dalbavancin, oritavancin, and telavancin. Drugs 70 859-886... [Pg.198]

See also in sourсe #XX -- [ Pg.475 , Pg.525 , Pg.526 , Pg.527 ]

See also in sourсe #XX -- [ Pg.352 ]

See also in sourсe #XX -- [ Pg.37 ]

See also in sourсe #XX -- [ Pg.15 , Pg.327 , Pg.328 , Pg.331 ]

See also in sourсe #XX -- [ Pg.705 , Pg.706 ]

See also in sourсe #XX -- [ Pg.520 ]

See also in sourсe #XX -- [ Pg.369 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...